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ABSTRACT 29 
Background/Aims: The pathogenesis of human polyomavirus KI, WU, MW and STL has not 30 
been elucidated yet. Respiratory transmission is suggested, but the site of the replication, 31 
tissue and cell tropism is not clarified. KIPyV and WUPyV DNA and/or antigen were 32 
detected in normal lung tissues previously by others. In fact, KIPyV DNA sequence was 33 
found in lung cancer samples. Up to date, there is no publication about the DNA prevalence 34 
of MWPyV and STLPyV neither in normal nor in cancerous lung tissues. The aim of the 35 
present study was to examine DNA prevalence of these polyomaviruses in cancerous and non-36 
cancerous lung tissue samples, in order to study the possible site for viral replication and/or 37 
persistence, and the potential association of these viruses with lung carcinogenesis, as well.  38 
Methods: 100 cancerous and 47 non-cancerous, formalin-fixed paraffin-embedded lung tissue 39 
samples were studied for KIPyV, WUPyV, MWPyV and STLPyV by real-time PCR. 40 
Results and conclusion: Neither of the viruses was found in samples from small cell, non-41 
small cell (adenocarcinoma, squamous cell carcinoma and large cell neuroendocrine lung 42 
cancer), mixed type and non-differentiated lung carcinoma, and non-cancerous lung tissues 43 
(from patients with pneumonia, emphysema and fibrosis).  44 
 45 
INTRODUCTION 46 
Members of the family Polyomaviridae are in growing numbers during the last 47 
decade, but only the “old” human polyomaviruses (PyV) BK and JC, the novel Merkel cell 48 
polyomavirus (MCPyV) and Trichodysplasia spinulosa–associated polyomavirus are linked to 49 
diseases. Pathogenesis of the other human polyomaviruses has not been clarified [1]. 50 
Human polyomavirus KI and WU (KIPyV and WUPyV) were described as new viral 51 
genomes from respiratory samples in 2007 [2, 3]. Later, both viruses were found mainly in 52 
respiratory samples: the viruses were detected (positivity rates are shown in brackets) in 53 
respiratory secretions (0.5-6.5 % for KIPyV and 0.35-16.4 % for WUPyV) and in tonsillar 54 
tissue samples (2 % for KIPyV and 2.2-12 % for WUPyV) [4-10]; and  both viruses was 55 
demonstrated in non-cancerous lung tissues (3.3 and 9.5 % for KIPyV and  case studies to 56 
detect antigens of WUPyV and KIPyV) [11-15], while WUPyV was found in 7.8 and 27.7 % 57 
of adenoids studied [6, 7], as well. MW polyomavirus (MWPyV) genome was discovered 58 
from stool sample in 2012 [16], but beside stool samples (2.3 %), it was detected also  in a 59 
condyloma specimen [17], nasal swab  and nasopharyngeal aspirate samples (1.5-9.2%) [18, 60 
19], tonsils (2 and 6 %) and adenoid tissue (1 %) [8, 20]. STL  polyomavirus (STLPyV) 61 
complete genome was also found in 0.25-1.1 % of faecal samples studied [21], but it was 62 
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detected in 2% of  tonsillar tissue samples analyzed, as well [8].   63 
Based on seroepidemiological studies these viruses are ubiquitous in the human 64 
population, childhood primary infections are suggested, and seropositivities increase with age. 65 
Seropositivity rates are 55-91% for KIPyV, 69-98% for WUPyV, 42-99 % [22-25] for 66 
MWPyV [25-27] and 68-70% for STLPyV [28]. Since all the studied viruses are ubiquitous 67 
and have been detected in respiratory and faecal samples, respiratory and/or faecal-oral 68 
transmission is suggested.  69 
Despite the oncogenic potential of all human pathogenic polyomaviruses linked to 70 
large and small tumour antigens (LTAg and sTAg), only MCPyV is thought to be an 71 
ethiologic agent in tumourigenesis, namely Merkel cell carcinoma [29, 30]. The association 72 
between seropositivity for KIPyV and for WUPyV and lung cancer was studied previously, 73 
antibodies against VP1 (viral protein 1) and sTAg were detected and analysed. Colombara et 74 
al. found that previous infections with these polyomaviruses were not associated with lung 75 
cancer [31, 32]. DNA prevalence of KIPyV and WUPyV was studied in different cancer types 76 
[9, 11-13, 33-39], but only KIPyV was detected in lung carcinomas [11] and in benign skin 77 
tumour [35]. To date, DNA prevalence of MWPyV was examined and detected in tonsillar 78 
cancer [9], but it was not found in mucosal melanoma [33] . STLPyV was studied only in 79 
tonsillar cancer, but the virus was not detected [9].  80 
The aim of the present study was to examine the DNA prevalence of KIPyV, WUPyV, 81 
MWPyV and STLPyV in cancerous and non-cancerous lung tissue samples, in order to study 82 
the possible site for viral replication and/or persistence, and the potential association of these 83 
viruses with lung carcinogenesis, as well.  84 
 85 
MATERIALS AND METHODS 86 
Patients and samples 87 
The study was approved by Regional and Institutional Ethics Committee, University 88 
of Debrecen (IX-R-052/00016-29/2012).  89 
One hundred and forty seven formalin-fixed paraffin-embedded lung tissue samples 90 
from 143 patients diagnosed routinely between 2012 and 2016 in Department of Pathology, 91 
University of Debrecen were analysed. Data of patients and numbers of cancerous and non-92 
cancerous samples are detailed in Table 1. Nucleic acid isolation was performed from a 93 
10 µM tissue section using High Pure FFPET DNA Isolation Kit (Roche, Switzerland) 94 
according to the manufacturer‟s instruction. Deparaffinization was carried out with xylene 95 
according to the protocol of the kit.  96 
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Quality and quantity of nucleic acid were checked by a NanoDrop 2000c 97 
Spectrophotometer (Thermo Scientific, USA). 98 
 99 
Detection of KIPyV, WUPyV, MWPyV and STLPyV DNA 100 
 Human polyomaviruses were detected by quantitative, real-time PCR (qPCR) in an 101 
Applied Biosystem 7500 real-time PCR instrument and analysed by 7500 Software v2.0.6 102 
(Applied Biosystems, USA). To control nucleic acid isolation, PCR with human β-globin 103 
primers PCO3 and PCO4 was carried out as detailed previously [39]. Primers used are 104 
summarized in Table 2. 105 
Protocol for KIPyV and WUPyV qPCR and positive controls were the same as 106 
described previously [39]. Plasmid containing KI polyomavirus isolate Stockholm 60 and AP-107 
p002 plasmid with the half genome of WU polyomavirus were kindly provided by Tobias 108 
Allander and David Wang. 109 
MWPyV qPCR was carried out with 5 µL template nucleic acid using primers ES105 110 
and ES106, probe ES107 and protocol as described by Siebrasse et al. [16]. A partial 111 
sequence of Malawi polyomavirus (GenBank: JQ898291.1, from 3966 nt to 4927 nt) was 112 
synthesized and cloned into pOK vector (GeneArt Gene Synthesis), than served as a positive 113 
control in qPCR.   114 
STLPyV DNA was detected in 5µL nucleic acid by qPCR published by Bialasiewicz 115 
et al. using 6.25-6.25 pmol STL-LT-F, STL-LT-R primers and 5 pmol STL-LT-Prb TaqMan 116 
probe (VIC-MGB) in a final volume of 25 µL [40]. STLPyV partial sequence (GenBank: 117 
JX463183.1, from 3922 nt  to 4776 nt) was sythesized (GeneArt Gene Synthesis), cloned into 118 
pJET1.2/blunt vector (Thermo Fisher Scientific, USA), than used as a positive control in 119 
qPCR.  120 
 121 
RESULTS AND DISCUSSION 122 
 Nucleic acid isolation was successful from 47 non-cancerous lung tissue samples and 123 
100 cancerous lung tissue samples proved by human β-globin PCR: amplifiable, good 124 
quantity DNA presented in each sample. Mean and median concentration of nucleic acid was 125 
164 and 152 ng/µL; the range of A260/A280 ratio was 1.68-2.05 (median 1.86).  126 
 Tissue samples from small cell, non-small cell (adenocarcinoma, squamous cell 127 
carcinoma and large cell, neuroendocrine lung cancer), mixed type and non-differentiated 128 
lung carcinoma, and samples from non-cancerous lung tissues (from patients with pneumonia, 129 
emphysema and fibrosis) were negative for KIPyV, WUPyV, MWPyV and STLPyV DNA.  130 
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 Despite the prevalence studies and growing number of data published, the 131 
pathogenesis of KIPyV, WUPyV, MWPyV and STLPyV has not been clarified. KIPyV and 132 
WUPyV were examined and found (positivity rates are shown in brackets) most frequently in 133 
respiratory secretions (0.35-16.4 % for KIPyV and 0.5-6.5% for WUPyV), but also in stool 134 
(0.5-11.6 % for KIPyV and 0.5-8.1 % for WUPyV), cerebrospinal fluid (1.6 %  for WUPyV), 135 
blood (1-3.2 % for KIPyV DNA and 0.8-4.6 % for WUPyV) and urine (2 % for KIPyV and 136 
12 % for WUPyV), suggesting that these viruses spread within the body and may establish 137 
persistent, even latent infection [4, 41]. Different (other than blood) tissue samples – normal 138 
and malignant, fresh or archived (frozen or formalin-fixed paraffin-embedded) – were also 139 
examined. Results published are summarized to date in Table 3.  As mentioned previously, 140 
based on the prevalence data, direct human-to-human, indirect (via food, water or surfaces), 141 
respiratory and/or faecal-oral transmission are suggested [42, 43]. Respiratory transmission 142 
and portal entry is also strengthened by some prevalence data of studies with tissue samples 143 
from the respiratory tract, namely adenoids, tonsils and lung. In adenoid samples only 144 
WUPyV DNA was found, but KIPyV was not [6, 7]. WUPyV was detected in tonsillar tissues 145 
in each study [5-10] , but KIPyV was found in two tonsils only by Peng et al [8]. Beside 146 
these, both viruses were detected in brain autopsy samples [44], in lymphoid tissues [14, 45], 147 
and examined, but not found in various, non-cancerous tissue samples detailed in Table 3. 148 
[13, 46].  MWPyV was also detected in respiratory samples [18, 19], in one adenoid tissue 149 
[20] , and in tonsils, but only in two [8, 20] out of the four studies [8-10, 20] Interestingly, 150 
tonsillar squamous cell carcinoma samples were positive for MWPyV DNA, but were 151 
negative for KIPyV, WUPyV and STLPyV [9].  STLPyV was detected in tonsillar samples in 152 
one study [8], while others did not find the viral sequence in tonsillar tissue samples [9, 10]. 153 
 Normal and cancerous lung tissue samples have been studied previously by two 154 
research teams for the presence of KIPyV DNA, nucleic acid isolation was carried out from 155 
fresh samples [11, 12]. Babakir-Mina et al. found high rate of KIPyV VP1 DNA positivity in 156 
cancerous lung tissue samples (9/20; 45%), and they detected viral VP1 sequence in one 157 
normal lung tissue sample surrounding the tumour, and in a lung biopsy from a transplant 158 
child  (2/21; 9.5 %), as well. However, only two cancerous lung samples were positive using 159 
other PCR targeting the early region of the virus [11]. Teramoto et al. examined KIPyV and 160 
WUPyV in 30 lung adenocarcinoma tissues and 30 adjacent, normal lung sample pairs, but 161 
only KIPyV was detected in one normal lung tissue [12]. Toptan et al. developed a pan-162 
human polyomavirus immunohistochemistry test and analyzed 1250 samples from various, 163 
also lung tumours and normal tissues (detailed in Table 3.), and antigen positivity was 164 
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revealed in a lung tissue sample from a patient with chronic lymphocytic leukaemia, then the 165 
presence of WUPyV DNA was also proved [13]. Siebrasse et al. studied KIPyV and WUPyV 166 
in lung tissue samples from two patients not only by PCR, but also by antibodies, revealing 167 
antigen positivity [14, 15]. KIPyV positive cells were identified as CD68+, suggesting that 168 
alveolar macrophages might be infected by the virus. Beside lung, other tissue samples were 169 
also examined, and KIPyV antigen positivity was detected in a spleen sample [14]. 170 
Immunohistochemistry was performed on lung, trachea, liver, kidney, and gastrointestinal 171 
tract tissue sections from a bone marrow transplant patient by anti-VP1 WUPyV antibody. 172 
Viral antigen positive cells were found in trachea and lung sections, some cells were CD68+ 173 
and showed macrophage morphology [15].  174 
 Other cancerous tissue samples – detailed in Table 3. – have been examined for 175 
KIPyV, WUPyV and MWPyV yet, but beside the above mentioned, KIPyV was detected 176 
solely in Spitz naevus, a benign tumour [35].  177 
 Based on immunohistochemistry and PCR studies, it is suggested that KIPyV 178 
and WUPyV may infect lung (even productively), but it requires more data to prove. To our 179 
knowledge, DNA prevalence of MWPyV and STLPyV have not been studied in lung tissue 180 
samples before this study. The PCR methods used in this study were developed and tested 181 
previously [16, 40, 47], it has high importance to compare data. Although we examined 182 
higher number of cancerous (n=100) and non-cancerous lung (n=47) tissue samples in the 183 
present study than was studied in any previous one, all were negative for KIPyV, WUPyV, 184 
MWPyV and STLPyV DNA by PCR.  Despite the possible oncogenic potential 185 
hypothetically linked to LTAg and STAg, and that DNA of KIPyV and MWPyV was detected 186 
in cancerous tissue samples, further epidemiological studies with high number of cancerous 187 
and non-cancerous tissues, and in vitro studies, as well are essential to evaluate whether these 188 
novel polyomaviruses are ethiological agent in tumourigenesis or not. 189 
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Table 1. Data of patients and tissue samples 344 
 Tissue samples 
number of patients / 
number of samples 
female male 
age (year) of 
patients:  
min-max (median) 
lu
n
g
 c
a
rc
in
o
m
a
 
small cell carcinoma 4/4 2 2 53.4-67 (65.4) 
non-small cell 
carcinoma 
squamous cell 
carcinoma 
17/17 3 14 57.7-75.9 (66.4) 
adenocarcinoma 69/71 37 32 38.3-73.3 (61.3) 
large cell 
neuroendocrine 
carcinoma 
2/2 1 1 28.1-56.5 
mixed type carcinoma 4/4 2 2 45-71.6 (59.6) 
non-differentiated type lung carcinoma 2 1 1 35.6-61.9 
total 98/100 46 52 28.1-77.3 (61.8) 
co
n
tr
o
l lung tissue sample from patients with 
pneumonia, fibrosis or emphysema 
45/47 21 24 13.1-78.8 (59.6) 
total 143/147 67 76 13.1-78.8 (61.5) 
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Table 2. Details of PCR used 
PCR 
Primer 
name 
Sequence 5’→ 3’ 
Target 
gene 
Amplicon 
size (bp) 
Sensitivity of 
PCR 
GEq/PCR 
 
Reference 
KIPyV and 
WUPyV, duplex, 
real-time PCR 
 
KIPyV 
VP2-3F 
CTATCCCTGAATACCAGTTGGAAAC 
VP2-3 74 5 
[47] 
KIPyV 
VP2-3R 
GTATGACGCGACAAGGTTGAAG 
KIPyV 
VP2-3 
probe 
FAM- TTCCGGGCATCCCAGACTGGC-
MGBNFQ 
WUPyV 
VP1F 
AACCAGGAAGGTCACCAAGAAG 
VP1 76 5 
WUPyV 
VP1R 
TCTACCCCTCCTTTTCTGACTTGT 
WUPyV 
VP1 probe 
NED-
CAACCCACAAGAGTGCAAAGCCTTCC-
MGBNFQ 
MWPyV real-
time PCR 
 
ES105 TGAGAAGGCCCCGGTTCT 
LT 73 10 [16] ES106 GAGGATGGGATGAAGATTTAAGTTG 
ES107 FAM-CCTCATCACTGGGAGC-MGBNFQ 
STLPyV real-
time PCR 
 
STL-LT-F TGCAGAGGTCCCTTCATCATC 
LT 132 10 
 
[40] 
STL-LT-R TTTTCTTTTTAGGGCGGACAATAT 
STL-LT-
Prb 
VIC- 
CCACCATTGCTCCCAAGCAGGAGTAC –
MGBNFQ  control PCR for 
human DNA 
 
PCO3 ACACAACT TGTTCACTAGC human 
beta-globin 
gene 
110 no data [39] 
PCO4 CAACTTCATCCACGTTCACC 
VP1: viral protein 1 gene; VP2: viral protein 2 gene; VP3: viral protein 3 gene; LT: large T antigen gene 
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KIPyV: KI polyomavirus; WUPyV: WU polyomavirus; MWPyV: MW polyomavirus; STLPyV: STL polyomavirus  
GEq/PCR: genome equivalent / PCR 
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Table 3. Prevalence of human polyomavirus 3, 4, 10 and 11 in tumour and normal tissue 
samples based on literature 
   
number of positive samples/number of 
samples tested (%) 
 reference tissue 
KIPyV 
(KIPyV) 
WUPyV 
(WUPyV) 
MWPyV 
(MWPyV) 
STLPyV 
(STLPyV) 
tu
m
o
u
r 
ti
ss
u
es
 
[33] 
mucosal melanoma 
0/55 0/55 0/55 nd 
[34] 0/38 0/38 nd nd 
[35] 
Spitz naevus 
4/25 
(16%) 
0/25 nd nd 
keratoacanthoma 0/22 0/22 nd nd 
[36] 
CNS tumours 
(ependyoma, 
astrocytoma, 
medulloblastoma, other 
gliomas, other 
neoplasms) 
0/25 0/25 nd nd 
neuroblastoma 0/31 0/31 nd nd 
[37] 
neuroendocrine 
tumours (brain, thymus, 
digestive system, lung, 
skin, thyroid gland) 
0/50 0/50 nd nd 
[38] 
neuroendocrine 
tumours (lung, 
gastrointestinal tract, 
female reproductive 
system, soft tissue, 
head and neck region, 
bladder) 
 
0/74 
0/74 nd nd 
[39] 
renal neoplasia 
(adenoma, 
angiomyolipoma, 
oncocytoma, 
0/187 0/187 nd nd 
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leiomyosarcoma, 
carcinoma renocellulare 
renis) and bladder 
uroepithelial carcinoma 
) 
[11] lung cancer 
9/20 
(45%) 
nd nd nd 
[12] lung adenocarcinoma 0/30 0/30 nd nd 
[13] 
lung adenocarcinoma 
(n=136), lung 
squamous cell 
carcinoma (n=100), 
oral cavity, stomach, 
colon, bladder, kidney, 
skin, breast, brain, 
mesothelium tomours,  
Non-Hodgkin‟s 
lymphoma tumour 
0*/1157 0*/1157 0*/1157 0*/1157 
[9] 
tonsillar squamous 
cell carcinoma 
0/38 0/38 
7/38 (18.4 
%) 
0/38 
n
o
rm
a
l 
ti
ss
u
es
 
[44] brain autopsy 
8/54 
(14.8%) 
6/54 
(11.1%) 
nd nd 
[12] 
lung 
1/30 
(3.3%) 
0/30 nd nd 
[11] 
2/21 
(9.5%) 
nd nd nd 
[14] 
2⃰/2 
(100%) 
nd nd nd 
[15] nd 1⃰/1 nd nd 
[13] 1*/1 0/1 0/1 0/1 
[15] trachea nd 1⃰/1 nd nd 
[8] tonsil 
2/99 
(2%) 
11/99 
(11.1%) 
2/99 (2%) 2/99 (2%) 
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[20] nd nd 
6/100 
(6%) 
nd 
[9] 0/40 
3/40 
(7.5%) 
0/40 0/40 
[10] 0/78 
3/78 
(3.8%) 
0/78 0/78 
[7] 0/51 
2/51 
(3.9%) 
nd nd 
[6] 0/50 
6/50 
(12%) 
nd nd 
[5] 0/229 
5/229 
(2.2%) 
nd nd 
[20] 
adenoid 
nd nd 
1/100 
(1%) 
nd 
[7] 0/51 
4/51 
(7.8%) 
nd nd 
[6] 0/83 
23/83 
(27.7%) 
nd nd 
[45] 
lymphoid tissue 
(lymph node and 
spleen) 
4/97 
(4.1%) 
3/97 
(3.1%) 
nd nd 
[14] 
lymphoid tissue 
(lymph node and 
spleen) 
1⃰/4 nd nd nd 
 
[13] 
stomach, colon, 
bladder, kidney, skin, 
brain, mesothelium, 
Non-Hodgkin‟s 
lymphoma 
0*/93 0*/93 0*/93 
0* 
/93 
[46] 
placenta, heart and liver 
from foetus 
0/535 0/535 nd nd 
nd: no data, not examined 
KIPyV: KI polyomavirus  
16 
 
WUPyV: WU polyomavirus  
MWPyV: MW polyomavirus  
STLPyV: STL polyomavirus  
⃰  antigen was detected by immunohistochemistry assay 
 
